IntroductionTo test drugs with the potential to prevent the onset of Parkinson’s disease (PD), it is key to identify individuals in the general population at high risk of developing PD. This is often difficult because most of the clinical markers are non-specific, common in PD but also common in older adults (e.g., sleep problems).ObjectiveWe aimed to identify the clinical markers at high specificity for developing PD by comparing individuals with PD or prodromal PD to healthy controls.MethodsWe investigated motor and non-motor symptoms (Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part 1 and 2 items) in 64 prodromal PD and 422 PD individuals calculating the odds ratios, adjusting for age and gender, for PD and prodrom...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
The underlying pathology of Parkinson’s disease (PD) is already well established by the time a diagn...
Introduction: To test drugs with the potential to prevent the onset of Parkinson’s disease (PD), it ...
Background: The detection of prodromal Parkinson’s disease (PD) is desirable to test drugs with neur...
Background: The detection of prodromal Parkinson’s disease (PD) is desirable to test drugs with neur...
The research was funded by Parkinson’s UK and supported by the National Institute for Health Researc...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical on...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
This article describes research criteria and probability methodology for the diagnosis of prodromal ...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
The underlying pathology of Parkinson’s disease (PD) is already well established by the time a diagn...
Introduction: To test drugs with the potential to prevent the onset of Parkinson’s disease (PD), it ...
Background: The detection of prodromal Parkinson’s disease (PD) is desirable to test drugs with neur...
Background: The detection of prodromal Parkinson’s disease (PD) is desirable to test drugs with neur...
The research was funded by Parkinson’s UK and supported by the National Institute for Health Researc...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical on...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
This article describes research criteria and probability methodology for the diagnosis of prodromal ...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical ons...
The underlying pathology of Parkinson’s disease (PD) is already well established by the time a diagn...